HC Wainwright reaffirmed their buy rating on shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in a report issued on Thursday morning.
A number of other analysts have also commented on BPTH. Zacks Investment Research lowered Bio-Path Holdings from a buy rating to a hold rating in a research report on Wednesday, July 12th. Maxim Group set a $2.00 target price on Bio-Path Holdings and gave the company a buy rating in a research report on Wednesday, April 5th.
Shares of Bio-Path Holdings (BPTH) traded down 3.70% during midday trading on Thursday, hitting $0.38. The company’s stock had a trading volume of 308,384 shares. The company’s market cap is $36.35 million. The company has a 50-day moving average price of $0.39 and a 200 day moving average price of $0.68. Bio-Path Holdings has a 1-year low of $0.33 and a 1-year high of $1.75.
Bio-Path Holdings (NASDAQ:BPTH) last issued its earnings results on Thursday, May 11th. The company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.01. On average, equities research analysts predict that Bio-Path Holdings will post ($0.07) EPS for the current year.
A number of hedge funds have recently modified their holdings of the stock. Tower Research Capital LLC TRC purchased a new stake in shares of Bio-Path Holdings during the first quarter worth approximately $105,000. Bank of New York Mellon Corp raised its stake in shares of Bio-Path Holdings by 1.7% in the first quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock worth $257,000 after buying an additional 5,172 shares during the last quarter. Sabby Management LLC raised its stake in shares of Bio-Path Holdings by 3.5% in the first quarter. Sabby Management LLC now owns 687,398 shares of the company’s stock worth $569,000 after buying an additional 23,352 shares during the last quarter. Finally, HighTower Advisors LLC raised its stake in shares of Bio-Path Holdings by 9.1% in the first quarter. HighTower Advisors LLC now owns 1,263,070 shares of the company’s stock worth $1,043,000 after buying an additional 105,000 shares during the last quarter. 19.88% of the stock is owned by institutional investors and hedge funds.
Bio-Path Holdings Company Profile
Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.
Receive News & Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
